FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to highly stable carbidopa-based pharmaceutical compositions comprising an antioxidant combination consisting of ascorbic acid and at least one additional antioxidant, wherein said combination strongly inhibits carbidopa degradation. These compositions may further comprise levodopa and one or both of arginine and meglumine.
EFFECT: compositions are beneficial in treatment of a disease, disorder or condition associated with loss of dopamine or dopaminergic neurons, for example, Parkinson's disease.
31 cl, 5 dwg, 31 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATMENT OF PARKINSON'S DISEASE | 2014 |
|
RU2677278C2 |
| CONTINUOUS ADMINISTRATION OF L-DOPA, INHIBITORS OF DOPA-DECARBOXYLASE, INHIBITORS OF CATECHOL-O-METHYLTRANSFERASE AND COMPOSITIONS, INTENDED FOR IT | 2011 |
|
RU2607497C2 |
| CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA DECARBOXYLASE INHIBITORS, CATECHOL-METHYLTRANSFERASE INHIBITORS AND INTENDED FOR THIS COMPOSITION | 2011 |
|
RU2740080C2 |
| COMPOSITIONS FOR CONTINUOUS ADMINISTRATION OF DOPA-DECARBOXYLASE INHIBITORS | 2010 |
|
RU2678839C2 |
| COMPOSITIONS FOR CONTINUOUS CONTROL OF DOPA-DECARBOXYLASE INHIBITORS | 2010 |
|
RU2559083C9 |
| COMPOSITIONS CONTAINING APOMORPHINE AND ORGANIC ACIDS, AND USING THEM | 2013 |
|
RU2688672C2 |
| APPARATUS FOR SUBCUTANEOUS DELIVERY OF A FLUID MEDICINAL PRODUCT | 2018 |
|
RU2765171C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | 2009 |
|
RU2540470C9 |
| CARBIDOPA AND L-DOPA PRODRUGS AND USE THEREOF FOR TREATING PARKINSON'S DISEASE | 2015 |
|
RU2743347C2 |
| POLYPHENOL-BASE PHARMACEUTICAL COMPOSITION POSSESSING NUTRIENT PROPERTIES AND ITS USING IN CANCER TREATMENT | 2003 |
|
RU2301666C2 |
